References
- Bateman ED, Bousquet J, Busse WW et al. Stability of asthma control with regular treatment: an analysis of the gaining optimal asthma controL (GOAL) study. Allergy63, 932–938 (2008).
- Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet368, 804–813 (2006).
- Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med.364, 1695–1707 (2011).
- Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol.108, 184–190 (2001).
- Brightling C, Berry M, Amrani Y. Targeting TNF-α: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol.121, 5–10 (2008).
- Holgate ST, Noonan M, Chanez P et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a controlled trial. Eur. Respir. J.37, 1352–1359 (2011).
- Wenzel SE, Barnes PJ, Bleecker ER et al. A randomized, double-blind, placebo-controlled study of tumor necrosis-α blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med.179, 549–558 (2009).
- Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med.176, 1062–1071 (2007).
- Wegmann M, Goggel R, Sel S et al. Effects of a low-molecular-weigh CCR-3 antagonist on chronic experimental asthma. Am. J. Respir. Cell Mol. Biol.36, 61–67 (2007).
- Hart TK, Blackburn MN, Brigham-Burke M et al. Preclinical efficacy and safety of pascolizumab (SB240683): a humanized anti-interleukin 4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol.130, 93–100 (2002).
- Holgate ST. Pathophysiology of asthma: what has our current understanding taught us about new therapeutic approaches. J. Allergy Clin. Immunol.128(3), 495–505 (2011).
- Singh D, Kane B, Molfino NA, Faggioni R, Roskos L, Woodcock A. A Phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm. Med.10, 3–11 (2010).
- Rosenwasser LJ, Busse WW, Lizambri RG, Olejnik TA, Totoritis MC. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a Phase 1, single-dose, dose-escalating clinical trial. J. Allergy Clin. Immunol.112, 563–570 (2003).
- Vultaggio A, Maggi E, Matucci A. Immediate adverse reactions to biologicals from pathogenic mechanisms to prophylactic management. Curr. Opin. Allergy Clin. Immunol.11, 262–268 (2011).